{"transactions":[{"id":976289,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":71991,"kind":"person","name":"Zuraw Qing Che","position":1,"cik":"0002079210","reported_name":"Zuraw Qing Che","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-09T13:00:09.000Z","date":"2025-12-05","kind":"grant","planned":false,"acquired":true,"shares":218652,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price of the stock option award is $8.18 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the date 24 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the Inducement Plan); and (iii) 30 days prior to the option's original expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On December 5, 2025, pursuant to the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan (the \"2021 Plan\") and 2023 Inducement Plan (the \"Inducement Plan\"), the Issuer's Board of Directors approved a stock option award repricing, effective as of December 5, 2025 (the \"Effective Date\"). Except for the new exercise price (see footnote 4 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/4th of the shares underlying the option vest on July 17, 2026, with the remainder vesting in substantially equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date."}],"balance_after":218652,"derivative":{"exercise_price":8.18,"expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":218652},"source":{"system":"sec-edgar","filing":"0002079210-25-000003","document":"form4-12092025_081203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000207921025000003/form4-12092025_081203.xml","form_type":"4"}},{"id":976288,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":71991,"kind":"person","name":"Zuraw Qing Che","position":1,"cik":"0002079210","reported_name":"Zuraw Qing Che","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-09T13:00:09.000Z","date":"2025-12-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":218652,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The amounts herein reflect the reverse stock split."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On December 5, 2025, pursuant to the terms of the Issuer's Amended and Restated 2021 Equity Incentive Plan (the \"2021 Plan\") and 2023 Inducement Plan (the \"Inducement Plan\"), the Issuer's Board of Directors approved a stock option award repricing, effective as of December 5, 2025 (the \"Effective Date\"). Except for the new exercise price (see footnote 4 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The amounts herein reflect the reverse stock split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/4th of the shares underlying the option vest on July 17, 2026, with the remainder vesting in substantially equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The amounts herein reflect the reverse stock split."}],"balance_after":0,"derivative":{"exercise_price":47.6,"expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":218652},"source":{"system":"sec-edgar","filing":"0002079210-25-000003","document":"form4-12092025_081203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000207921025000003/form4-12092025_081203.xml","form_type":"4"}},{"id":1079195,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":71991,"kind":"person","name":"Zuraw Qing Che","position":1,"cik":"0002079210","reported_name":"Zuraw Qing Che","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-07-30T20:03:38.000Z","date":"2025-07-17","kind":"grant","planned":false,"acquired":true,"shares":4373040,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4th of the shares underlying the option vest on July 17, 2026, with the remainder vesting in substantially equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date."}],"balance_after":4373040,"derivative":{"exercise_price":2.38,"expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":4373040},"source":{"system":"sec-edgar","filing":"0001415889-25-020551","document":"form4-07302025_080734.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588925020551/form4-07302025_080734.xml","form_type":"4"}},{"id":1079194,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":71991,"kind":"person","name":"Zuraw Qing Che","position":1,"cik":"0002079210","reported_name":"Zuraw Qing Che","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2025-07-30T20:03:38.000Z","date":"2025-07-17","kind":"grant","planned":false,"acquired":true,"shares":937080,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares underlying restricted stock units (\"RSUs\"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. 1/4th of the RSUs vest on August 1, 2026, with the remainder vesting in substantially equal quarterly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date."}],"balance_after":937080,"source":{"system":"sec-edgar","filing":"0001415889-25-020551","document":"form4-07302025_080734.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588925020551/form4-07302025_080734.xml","form_type":"4"}}]}